AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 7, 2026Sponsor estimatePhase 3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc. · NMOSDActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 3NCT06607627PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc. · Generalized Myasthenia GravisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 3NCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and...AstraZeneca · AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT05303532Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With DurvalumabAstraZeneca · CancerEnrolling by invitationAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 4, 2027Sponsor estimatePhase 3NCT07000136A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHAstraZeneca · Heterozygous Familial HypercholesterolaemiaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2027Sponsor estimatePhase 3NCT05925803Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)AstraZeneca · Systemic SclerosisActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2027Sponsor estimatePhase 3NCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in...AstraZeneca · Non-Small Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2027Sponsor estimatePhase 3NCT06417814A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy...AstraZeneca · Metastatic Non-small Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2027Sponsor estimatePhase 3NCT07000123A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventAstraZeneca · Cardiovascular DiseaseActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2027Sponsor estimatePhase 3NCT06706817A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment...AstraZeneca · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 15, 2027Sponsor estimate | NCT02972840A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLAcerta Pharma BV · Lymphoma, Mantle Cell | AZNLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 15, 2027Sponsor estimatePhase 3NCT02972840A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLAcerta Pharma BV · Lymphoma, Mantle CellActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.